- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
Patent holdings for IPC class A61P 7/04
Total number of patents in this class: 1788
10-year publication summary
|
37
|
79
|
109
|
93
|
136
|
117
|
154
|
124
|
121
|
49
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bioverativ Therapeutics Inc. | 214 |
56 |
| Chugai Seiyaku Kabushiki Kaisha | 1393 |
29 |
| The Children's Hospital of Philadelphia | 838 |
27 |
| Takeda Pharmaceutical Company Limited | 2719 |
24 |
| Cellphire, Inc. | 109 |
24 |
| Genzyme Corporation | 1334 |
24 |
| Novo Nordisk A/S | 2301 |
19 |
| Laboratoire Francais du Fractionnement et des Biotechnologies | 296 |
17 |
| Novo Nordisk Health Care AG | 330 |
17 |
| CSL Behring Lengnau AG | 125 |
17 |
| Baxter International Inc. | 1891 |
16 |
| The University of North Carolina at Chapel Hill | 2069 |
16 |
| Baxter Healthcare S.A. | 1387 |
15 |
| Pfizer Inc. | 3362 |
13 |
| Baxalta Incorporated | 300 |
12 |
| The Trustees of the University of Pennsylvania | 4398 |
11 |
| Osaka University | 3309 |
11 |
| The General Hospital Corporation | 4803 |
10 |
| CSL Behring GmbH | 350 |
10 |
| CSL Limited | 249 |
10 |
| Other owners | 1410 |